1
|
Amato ME, Darling A, Stovickova L, Attard S, Eggink H, Engelen M, Freilinger M, Grosso S, Hadzsiev K, Moroni I, Nardocci N, Neubauer D, Nicita F, Pagliano E, Siegert S, Soler D, van de Pol LA, Vasco G, Vidailhet M, Willemsen MA, Zibordi F, Zorzi G, Zumrova A, Reinhard C, Sevin C, Wolf N, Rodriguez-Blazquez C, Sival DA, Ortigoza-Escobar JD. Improving paediatric movement disorders care: Insights on rating scales utilization and clinical practice. Eur J Paediatr Neurol 2024; 52:10-19. [PMID: 38970889 DOI: 10.1016/j.ejpn.2024.06.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/27/2024] [Revised: 06/22/2024] [Accepted: 06/29/2024] [Indexed: 07/08/2024]
Abstract
AIM This exploratory study evaluates rating scale usage by experts from the European Reference Network for Rare Neurological Diseases (ERN-RND) for paediatric MD, considering factors like diagnosis, intellectual disability, age, and transition to adult care. The aim is to propose a preliminary framework for consistent application. METHODS A multicentre survey among 25 ERN-RND experts from 10 European countries examined rating scale usage in paediatric MD, categorizing MD into acute, non-progressive, and neurodegenerative types. Factors influencing scale choice and the transition to adult care practices were analysed. A comprehensive literature search was conducted to identify the earliest age of application of these scales in paediatric patients. RESULTS The study identifies various rating scales and establishes their usage frequencies for different MDs. Experts highlighted the need for standardized scales and proposed preliminary evaluation strategies based on clinical contexts. Challenges in applying scales to young, non-cooperative patients were acknowledged. INTERPRETATION The study recommends developing standardized rating scales for paediatric MDs to improve evaluations and data collection. It suggests potential scales for specific clinical scenarios to better evaluate disease progression. Comprehensive, patient-centred care remains crucial during the transition to adult care, despite the identified challenges. This exploratory approach aims to enhance patient outcomes and care.
Collapse
Affiliation(s)
- María Eugenia Amato
- Department of Paediatric Neurology, Hospital Sant Joan de Déu, Barcelona, Spain
| | - Alejandra Darling
- Department of Paediatric Neurology, Hospital Sant Joan de Déu, Barcelona, Spain
| | - Lucie Stovickova
- Centre of Hereditary Ataxias, Department of Pediatric Neurology, Second Faculty of Medicine and Motol University Hospital, V Uvalu 84, 15006, Prague 5, Czech Republic
| | - Stephen Attard
- Pediatric Neurology Department, Mater Dei Hospital, Malta
| | - Hendriekje Eggink
- Department of Neurology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9700 RB, Groningen, the Netherlands
| | - Marc Engelen
- Department of Pediatric Neurology/Emma Children's Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, 1100 DD, the Netherlands
| | - Michael Freilinger
- Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
| | - Salvatore Grosso
- Clinical Pediatrics, Department of Molecular Medicine and Development, University of Siena, Siena, Italy
| | - Kinga Hadzsiev
- Department of Medical Genetics, Medical School, University of Pécs, Pécs, Hungary
| | - Isabella Moroni
- Department of Pediatric Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - Nardo Nardocci
- Department of Pediatric Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - David Neubauer
- Department of Child, Adolescent & Developmental Neurology, University Children's Hospital, Ljubljana, Slovenia
| | - Francesco Nicita
- Unit of Neuromuscular and Neurodegenerative Disorders, IRCCS Bambino Gesù Children's Hospital, Rome, Italy
| | - Emanuela Pagliano
- Department of Pediatric Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - Sandy Siegert
- Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
| | - Doriette Soler
- Pediatric Neurology Department, Mater Dei Hospital, Malta
| | - Laura A van de Pol
- Department of Child Neurology, Amsterdam UMC, Vrije Universiteit, De Boelelaan, 1117, Amsterdam, the Netherlands; Emma Children's Hospital, Amsterdam UMC, Meibergdreef 9, Amsterdam, the Netherlands
| | - Gessica Vasco
- Unit of Neurorehabilitation, Department of Neuroscience and Neurorehabilitation, IRCCS Bambino Gesù Children's Hospital, Rome, Italy
| | - Marie Vidailhet
- Department of Neurology, Sorbonne University, Paris Brain Institute - ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France
| | - Michel Aap Willemsen
- Department of Pediatric Neurology, Donders Centre for Neuroscience, Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Federica Zibordi
- Department of Pediatric Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - Giovanna Zorzi
- Department of Pediatric Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - Alena Zumrova
- Centre of Hereditary Ataxias, Department of Pediatric Neurology, Second Faculty of Medicine and Motol University Hospital, V Uvalu 84, 15006, Prague 5, Czech Republic
| | - Carola Reinhard
- Institute for Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany; Centre for Rare Diseases, University Hospital Tübingen, Tübingen, Germany
| | - Caroline Sevin
- Pediatric Neurology Department, Hôpital Bicêtre, Le Kremlin Bicêtre, France
| | - Nicole Wolf
- Department of Child Neurology, Amsterdam Leukodystrophy Center, Amsterdam UMC Location Vrije Universiteit Amsterdam, Emma's Children's Hospital, Boelelaan, 1117, Amsterdam, the Netherlands; Amsterdam Neuroscience, Cellular & Molecular Mechanisms, Amsterdam, the Netherlands
| | | | - Deborah A Sival
- Expertise Center Movement Disorders Groningen, University Medical Center Groningen, Groningen, the Netherlands; Department of Pediatric Neurology, University of Groningen, University Medical Center Groningen, Beatrix Children's Hospital, Groningen, the Netherlands
| | - Juan Darío Ortigoza-Escobar
- Department of Paediatric Neurology, Hospital Sant Joan de Déu, Barcelona, Spain; U-703 Centre for Biomedical Research on Rare Diseases (CIBER-ER), Instituto de Salud Carlos III, Barcelona, Spain.
| |
Collapse
|
2
|
Tarrano C, Galléa C, Delorme C, McGovern EM, Atkinson-Clement C, Barnham IJ, Brochard V, Thobois S, Tranchant C, Grabli D, Degos B, Corvol JC, Pedespan JM, Krystkowiak P, Houeto JL, Degardin A, Defebvre L, Valabrègue R, Beranger B, Apartis E, Vidailhet M, Roze E, Worbe Y. Association of abnormal explicit sense of agency with cerebellar impairment in myoclonus-dystonia. Brain Commun 2024; 6:fcae105. [PMID: 38601915 PMCID: PMC11004927 DOI: 10.1093/braincomms/fcae105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 02/20/2024] [Accepted: 03/26/2024] [Indexed: 04/12/2024] Open
Abstract
Non-motor aspects in dystonia are now well recognized. The sense of agency, which refers to the experience of controlling one's own actions, has been scarcely studied in dystonia, even though its disturbances can contribute to movement disorders. Among various brain structures, the cerebral cortex, the cerebellum, and the basal ganglia are involved in shaping the sense of agency. In myoclonus dystonia, resulting from a dysfunction of the motor network, an altered sense of agency may contribute to the clinical phenotype of the condition. In this study, we compared the explicit and implicit sense of agency in patients with myoclonus dystonia caused by a pathogenic variant of SGCE (DYT-SGCE) and control participants. We utilized behavioural tasks to assess the sense of agency and performed neuroimaging analyses, including structural, resting-state functional connectivity, and dynamic causal modelling, to explore the relevant brain regions involved in the sense of agency. Additionally, we examined the relationship between behavioural performance, symptom severity, and neuroimaging findings. We compared 19 patients with DYT-SGCE and 24 healthy volunteers. Our findings revealed that patients with myoclonus-dystonia exhibited a specific impairment in explicit sense of agency, particularly when implicit motor learning was involved. However, their implicit sense of agency remained intact. These patients also displayed grey-matter abnormalities in the motor cerebellum, as well as increased functional connectivity between the cerebellum and pre-supplementary motor area. Dynamic causal modelling analysis further identified reduced inhibitory effects of the cerebellum on the pre-supplementary motor area, decreased excitatory effects of the pre-supplementary motor area on the cerebellum, and increased self-inhibition within the pre-supplementary motor area. Importantly, both cerebellar grey-matter alterations and functional connectivity abnormalities between the cerebellum and pre-supplementary motor area were found to correlate with explicit sense of agency impairment. Increased self-inhibition within the pre-supplementary motor area was associated with less severe myoclonus symptoms. These findings highlight the disruption of higher-level cognitive processes in patients with myoclonus-dystonia, further expanding the spectrum of neurological and psychiatric dysfunction already identified in this disorder.
Collapse
Affiliation(s)
- Clément Tarrano
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute—Institut du Cerveau et de la Moelle épinière, Inserm U1127, Paris 75013, France
- Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Neurology, Clinical Investigation Center for Neurosciences, Paris 75013, France
| | - Cécile Galléa
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute—Institut du Cerveau et de la Moelle épinière, Inserm U1127, Paris 75013, France
- Department of Research Neuroimaging, Centre de NeuroImagerie de Recherche (CENIR), Sorbonne Université, Paris 75013, France
| | - Cécile Delorme
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute—Institut du Cerveau et de la Moelle épinière, Inserm U1127, Paris 75013, France
- Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Neurology, Clinical Investigation Center for Neurosciences, Paris 75013, France
| | - Eavan M McGovern
- Department of Neurology, Beaumont Hospital, Dublin 9, D09 VY21, Ireland
- School of Medicine, Royal College of Surgeons in Ireland, Dublin 2, D02 YN77, Ireland
| | - Cyril Atkinson-Clement
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute—Institut du Cerveau et de la Moelle épinière, Inserm U1127, Paris 75013, France
- School of Medicine, University of Nottingham, Nottingham NG7 2RD, UK
| | | | - Vanessa Brochard
- Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Neurology, Clinical Investigation Center for Neurosciences, Paris 75013, France
| | - Stéphane Thobois
- Department of Neurology, Hospices Civils de Lyon, Lyon 69000, France
| | - Christine Tranchant
- Département de Neurologie, Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, Strasbourg 67098, France
- INSERM-U964/CNRS-UMR7104, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg, Illkirch 67404, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg 67000, France
| | - David Grabli
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute—Institut du Cerveau et de la Moelle épinière, Inserm U1127, Paris 75013, France
- Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Neurology, Clinical Investigation Center for Neurosciences, Paris 75013, France
| | - Bertrand Degos
- Department of Neurology, Assistance Publique-Hôpitaux de Paris, Avicenne Hospital, Sorbonne Paris Nord, Bobigny 93000, France
| | - Jean Christophe Corvol
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute—Institut du Cerveau et de la Moelle épinière, Inserm U1127, Paris 75013, France
- Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Neurology, Clinical Investigation Center for Neurosciences, Paris 75013, France
| | - Jean-Michel Pedespan
- Department of Neuropediatry, Universitary Hospital of Pellegrin, Bordeaux 33076, France
| | - Pierre Krystkowiak
- Department of Neurology, Abu Dhabi Stem Cells Centre, Abu Dhabi, United Arab Emirates
| | - Jean-Luc Houeto
- Department of Neurology CHU Limoges, Inserm U1094, IRD U270, Univ. Limoges, EpiMaCT—Epidemiology of chronic diseases in tropical zone, Institute of Epidemiology and Tropical Neurology, OmegaHealth, Limoges 87000, France
| | - Adrian Degardin
- Department of Neurology, Tourcoing Hospital, Tourcoing 59599, France
| | - Luc Defebvre
- Department of Neurology, University of Lille, Lille 59000, France
- Department of Neurology, Lille Centre of Excellence for Neurodegenerative Diseases » (LiCEND), Lille F-59000, France
| | - Romain Valabrègue
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute—Institut du Cerveau et de la Moelle épinière, Inserm U1127, Paris 75013, France
- Department of Research Neuroimaging, Centre de NeuroImagerie de Recherche (CENIR), Sorbonne Université, Paris 75013, France
| | - Benoit Beranger
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute—Institut du Cerveau et de la Moelle épinière, Inserm U1127, Paris 75013, France
- Department of Research Neuroimaging, Centre de NeuroImagerie de Recherche (CENIR), Sorbonne Université, Paris 75013, France
| | - Emmanuelle Apartis
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute—Institut du Cerveau et de la Moelle épinière, Inserm U1127, Paris 75013, France
- Department of Neurophysiology, Saint-Antoine Hospital, Paris 75012, France
| | - Marie Vidailhet
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute—Institut du Cerveau et de la Moelle épinière, Inserm U1127, Paris 75013, France
- Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Neurology, Clinical Investigation Center for Neurosciences, Paris 75013, France
| | - Emmanuel Roze
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute—Institut du Cerveau et de la Moelle épinière, Inserm U1127, Paris 75013, France
- Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Neurology, Clinical Investigation Center for Neurosciences, Paris 75013, France
| | - Yulia Worbe
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute—Institut du Cerveau et de la Moelle épinière, Inserm U1127, Paris 75013, France
- Department of Neurophysiology, Saint-Antoine Hospital, Paris 75012, France
| |
Collapse
|
3
|
Surillo-Dahdah L, Morfi-Pagán CA. Two-Generation Epsilon-Sarcoglycan Gene (SGCE) Mutation-Associated Myoclonus-Dystonia (DYT-SGCE) Misdiagnosed as Tourette's Syndrome: A Case Series. Cureus 2023; 15:e45289. [PMID: 37846277 PMCID: PMC10576872 DOI: 10.7759/cureus.45289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/15/2023] [Indexed: 10/18/2023] Open
Abstract
This case series provides a diagnosis of myoclonus-dystonia syndrome (MDS) in two patients whose original presentation was thought to be Tourette's syndrome. The first patient presented with dystonia and myoclonus, which progressively worsened with age, and was diagnosed with an epsilon-sarcoglycan gene (SGCE) mutation. The patient's father, who was diagnosed in his childhood with Tourette's syndrome, also received genetic testing, which proved that to be a misdiagnosis and confirmed that he was the carrier of the SGCE mutation. Both patients were subjected to a levodopa trial, which proved to be an effective treatment. To our knowledge, these are the first reported cases of heterozygous pathogenic mutation of SGCE in Puerto Rico.
Collapse
Affiliation(s)
- Laura Surillo-Dahdah
- Department of Neurology, Institute of Neuroscience, Manatí Medical Center, Manatí, PRI
| | | |
Collapse
|
4
|
Correa-Vela M, Carvalho J, Ferrero-Turrion J, Cazurro-Gutiérrez A, Vanegas M, Gonzalez V, Alvárez R, Marcé-Grau A, Moreno A, Macaya-Ruiz A, Pérez-Dueñas B. Early recognition of SGCE-myoclonus-dystonia in children. Dev Med Child Neurol 2023; 65:207-214. [PMID: 35723607 DOI: 10.1111/dmcn.15298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 03/20/2022] [Accepted: 05/03/2022] [Indexed: 01/09/2023]
Abstract
AIM To evaluate early dystonic features in children and adolescents with SGCE-myoclonus-dystonia. METHOD In this cross-sectional study, 49 patients (26 females and 23 males) with SGCE-myoclonus-dystonia (aged 15y 2mo, SD 12y) with childhood-onset (2y 10mo, SD 1y 10mo) dystonia were examined using a standardized video recorded protocol. Dystonia was rated using the Writer's Cramp and Gait Dystonia Rating Scales. Disability and impairment for handwriting and walking were also rated. RESULTS Dystonia was present at rest (n=1), posture (n=12), and during specific motor tasks (n=45) such as writing (n=35), walking (n=23), and running (n=20). Most children reported disability while performing these tasks. Early dystonic patterns were identified for writer's cramp and gait dystonia, the latter named the 'circular shaking leg', 'dragging leg', and 'hobby-horse gait' patterns. Sensory tricks were used by five and eight children to improve dystonia and myoclonus during writing and walking respectively. The rating scales accurately measured the severity of action dystonia and correlated with self-reported disability. INTERPRETATION Children with SGCE-myoclonus-dystonia show recognizable dystonic patterns and sensory tricks that may lead to an early diagnosis and timely therapeutic approach. Isolated writer's cramp is a key feature in childhood and should prompt SCGE analysis. The proposed action dystonia scales could be used to monitor disease course and response to treatment. WHAT THIS PAPER ADDS Most children with SGCE-myoclonus-dystonia got writer's cramp and had walking and running dystonia. Writer's cramp was a key feature and should prompt SGCE genetic investigation. 'Circular shaking leg', 'dragging leg', and 'hobby-horse gait' were recognized as early gait patterns. Children used sensory tricks to improve myoclonus and dystonia, suggesting common pathophysiological mechanisms. Action dystonia rating scales are valid tools to assess severity in children.
Collapse
Affiliation(s)
- Marta Correa-Vela
- Department of Pediatric Neurology, Vall d'Hebron Hospital Universitari, Pediatric.,Departament de Pediatria, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Joao Carvalho
- Pediatric Neurology, Centro de Desenvolvimento da Criança Torrado da Silva, Hospital Garcia de Orta. Almada, Portugal
| | | | | | - Maria Vanegas
- Department of Pediatric Neurology, Vall d'Hebron Hospital Universitari, Pediatric.,Paediatric Department, Evelina Children's Hospital, London, UK
| | | | - Ramiro Alvárez
- Department of Neurology, Hospital Germans Trias, Barcelona, Spain
| | - Anna Marcé-Grau
- Department of Pediatric Neurology, Vall d'Hebron Hospital Universitari, Pediatric
| | - Antonio Moreno
- Departament de Pediatria, Universitat Autònoma de Barcelona, Barcelona, Spain.,Department of Pediatrics, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.,CIBER of Rare Diseases (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - Alfons Macaya-Ruiz
- Department of Pediatric Neurology, Vall d'Hebron Hospital Universitari, Pediatric.,Departament de Pediatria, Universitat Autònoma de Barcelona, Barcelona, Spain.,Neurology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain
| | - Belén Pérez-Dueñas
- Department of Pediatric Neurology, Vall d'Hebron Hospital Universitari, Pediatric.,Departament de Pediatria, Universitat Autònoma de Barcelona, Barcelona, Spain.,CIBER of Rare Diseases (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.,Neurology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain
| |
Collapse
|
5
|
Cazurro-Gutiérrez A, Marcé-Grau A, Correa-Vela M, Salazar A, Vanegas MI, Macaya A, Bayés À, Pérez-Dueñas B. ε-Sarcoglycan: Unraveling the Myoclonus-Dystonia Gene. Mol Neurobiol 2021; 58:3938-3952. [PMID: 33886091 DOI: 10.1007/s12035-021-02391-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2021] [Accepted: 04/08/2021] [Indexed: 01/23/2023]
Abstract
Myoclonus-dystonia (MD) is a rare childhood-onset movement disorder, with an estimated prevalence of about 2 per 1,000,.000 in Europe, characterized by myoclonic jerks in combination with focal or segmental dystonia. Pathogenic variants in the gene encoding ε-sarcoglycan (SGCE), a maternally imprinted gene, are the most frequent genetic cause of MD. To date, the exact role of ε-sarcoglycan and the pathogenic mechanisms that lead to MD are still unknown. However, there are more than 40 reported isoforms of human ε-sarcoglycan, pointing to a complex biology of this protein. Additionally, some of these are brain-specific isoforms, which may suggest an important role within the central nervous system. In the present review, we aim to provide an overview of the current state of knowledge of ε-sarcoglycan. We will focus on the genetic landscape of SGCE and the presence and plausible role of ε-sarcoglycan in the brain. Finally, we discuss the importance of the brain-specific isoforms and hypothesize that SGCE may play essential roles in normal synaptic functioning and their alteration will be strongly related to MD.
Collapse
Affiliation(s)
- Ana Cazurro-Gutiérrez
- Paediatric Neurology Research Group, Hospital Vall d'Hebrón, Universitat Autònoma de Barcelona, Vall d'Hebrón Research Institute, Barcelona, Spain
- Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Anna Marcé-Grau
- Paediatric Neurology Research Group, Hospital Vall d'Hebrón, Universitat Autònoma de Barcelona, Vall d'Hebrón Research Institute, Barcelona, Spain
| | - Marta Correa-Vela
- Paediatric Neurology Research Group, Hospital Vall d'Hebrón, Universitat Autònoma de Barcelona, Vall d'Hebrón Research Institute, Barcelona, Spain
- Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Ainara Salazar
- Paediatric Neurology Research Group, Hospital Vall d'Hebrón, Universitat Autònoma de Barcelona, Vall d'Hebrón Research Institute, Barcelona, Spain
- Paediatric Neurology Department, Hospital Vall d'Hebron, Barcelona, Spain
| | - María I Vanegas
- Paediatric Neurology Research Group, Hospital Vall d'Hebrón, Universitat Autònoma de Barcelona, Vall d'Hebrón Research Institute, Barcelona, Spain
- Universitat de Barcelona, Barcelona, Spain
| | - Alfons Macaya
- Paediatric Neurology Research Group, Hospital Vall d'Hebrón, Universitat Autònoma de Barcelona, Vall d'Hebrón Research Institute, Barcelona, Spain
- Universitat Autònoma de Barcelona, Barcelona, Spain
- Paediatric Neurology Department, Hospital Vall d'Hebron, Barcelona, Spain
| | - Àlex Bayés
- Universitat Autònoma de Barcelona, Barcelona, Spain
- Molecular Physiology of the Synapse Laboratory, Biomedical Research Institute Sant Pau, Barcelona, Spain
| | - Belén Pérez-Dueñas
- Paediatric Neurology Research Group, Hospital Vall d'Hebrón, Universitat Autònoma de Barcelona, Vall d'Hebrón Research Institute, Barcelona, Spain.
- Universitat Autònoma de Barcelona, Barcelona, Spain.
- Paediatric Neurology Department, Hospital Vall d'Hebron, Barcelona, Spain.
| |
Collapse
|